Duality Advisers’s Emergent Biosolutions EBS Stock Holding History

Duality Advisers’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-77,298	Closed	-$913K	–	615
2022 Q4	$913K	Buy	77,298 +20,494	+36%	+$317K	0.1%	333
2022 Q3	$1.19M	Sell	56,804 -8,846	-13%	-$246K	0.13%	274
2022 Q2	$2.04M	Buy	65,650 +59,009	+889%	+$2.01M	0.2%	191
2022 Q1	$273K	Sell	6,641 -13,778	-67%	-$608K	0.03%	565
2021 Q4	$888K	Sell	20,419 -43,506	-68%	-$1.97M	0.1%	316
2021 Q3	$3.2M	Buy	63,925 +29,401	+85%	+$1.78M	0.25%	163
2021 Q2	$2.17M	Buy	34,524 +24,730	+253%	+$1.59M	0.19%	187
2021 Q1	$910K	Sell	9,794 -9,365	-49%	-$959K	0.08%	362
2020 Q4	$1.72M	Buy	19,159 +9,049	+90%	+$831K	0.13%	248
2020 Q3	$1.04M	Buy	+10,110	New	+$1.09M	0.07%	360

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Duality Advisers's EBS Position: Q1 2023 in Review

Duality Advisers sold out of Emergent Biosolutions (EBS) in Q1 2023, closing a stake of 77,298 shares — an estimated $913K sold.

Duality Advisers first reported a position in EBS in Q3 2020 and held it in 10 quarters. The position peaked at $3.2M in Q3 2021. 191 funds tracked by Wall St. Rank hold EBS as of Q1 2023.

Duality Advisers reported no remaining Emergent Biosolutions position as of Q1 2023 after selling out during the quarter.
Duality Advisers sold 77,298 Emergent Biosolutions shares in Q1 2023, an estimated $913K.
Duality Advisers first reported a position in Emergent Biosolutions in Q3 2020 and held it in 10 quarters.
Duality Advisers's Emergent Biosolutions position peaked at $3.2M in Q3 2021.
191 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2023.

Based on Duality Advisers's 13F filing for Q1 2023, filed 27 Jun 2023.